Caring Brands (NASDAQ:CABR) Posts Earnings Results

Caring Brands (NASDAQ:CABR) released its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, FiscalAI reports.

Caring Brands Stock Performance

Shares of NASDAQ CABR traded down $0.07 during trading hours on Thursday, hitting $1.31. The company’s stock had a trading volume of 56,078 shares, compared to its average volume of 108,697. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.62 and a current ratio of 5.66. The stock has a 50-day moving average price of $1.34. The stock has a market capitalization of $11.95 million and a PE ratio of -2.05. Caring Brands has a 12 month low of $0.71 and a 12 month high of $5.35.

Institutional Trading of Caring Brands

A hedge fund recently bought a new position in Caring Brands stock. Jane Street Group LLC acquired a new position in Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent filing with the Securities and Exchange Commission.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Caring Brands has an average rating of “Sell”.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.